Refine Results
  1. "Robert Motzer"
Formats
  1. Journal Article (539)
  2. Meeting Abstract (493)
  3. Book Section (20)
  4. Review (7)
  5. Conference Paper (6)
  6. Correspondence (4)
  7. Guidelines (4)
  8. Book Whole (2)
  9. Research Letter (1)
Groups
  1. Department of Medicine (1076)
  2. Genitourinary Oncology Service (1076)
  3. Solid Tumor Oncology Division (1076)
  4. Surgery (256)
  5. Urology (249)
  6. Survivorship Research (232)

More Groups

People
  1. Robert Motzer (1076)
  2. George Bosl (180)
  3. Darren Feldman (132)
  4. Martin Voss (132)
  5. Dean Bajorin (122)
  6. Joel Sheinfeld (108)

More People

Years
  1. 2022 (21)
  2. 2021 (64)
  3. 2020 (65)
  4. 2019 (66)
  5. 2018 (71)
  6. 2017 (50)

More Years

Publications
  1. Journal of Clinical Oncology (380)
  2. Annals of Oncology (67)
  3. BJU International (39)
  4. Cancer (33)
  5. European Journal of Cancer (32)
  6. Clinical Cancer Research (29)

More Publications

Publishers
  1. American Society of Clinical Oncology (382)
  2. Elsevier Science, Inc. (94)
  3. Oxford University Press (89)
  4. Elsevier Inc. (81)
  5. Wiley Blackwell (81)
  6. American Association for Cancer Research (50)

More Publishers

Results (1076)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; McDermott, D. F.; Escudier, B.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthélémy, P.; Plimack, E. R.; Porta, C.; George, S.; more...
    Cancer (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up
    Meeting Abstract

    Tannir, N. M.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; George, S.; Powles, T.; Donskov, F.; Tykodi, S. S.; Pal, S. K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era
    Meeting Abstract

    Shah, N. J.; Sura, S.; Shinde, R.; Shi, J. X.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting
    Meeting Abstract

    Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Perini, R. F.; Puneet, S.; Robert, N. J.; Vogelzang, N. J.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma
    Meeting Abstract

    Powles, T.; Choueiri, T. K.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Hamzaj, A.; Porta, C.; Hocking, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Motzer, R. J.; Albiges, L.; Choueiri, T. K.; Plimack, E. R.; Rini, B. I.; Suttner, L.; Yin, L.; Willemann-Rogerio, J.; Hammers, H. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146
    Meeting Abstract

    Lee, C. H.; Rasco, D. W.; Rao, A.; Taylor, M. H.; Hsieh, J. J.; Pinto, A.; Vogelzang, N. J.; Cao, Z. A.; Suttner, L.; Loboda, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; McHugh, D. J.; Dadoun, C.; Knezevic, A.; Carlo, M. I.; Feld, E.; Shapnik, N.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Hammers, H. J.; McKay, R. R.; Heng, D. Y. C.; Beckermann, K.; Kasturi, V.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results
    Meeting Abstract

    Cella, D.; Motzer, R. J.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J.; Zhang, J.; Simsek, B.; Ivanescu, C.; Choueiri, T. K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save